MARY BOURBON: Open Payments
NPI 1023499548 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$249 in 13 payments from 8 companies in 2025. Trend: 2023 $34 · 2024 $231 · 2025 $249
Food & beverage: $249
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 4 | $94 |
| ABBVIE INC. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Orexo US, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Indivior Inc. | 1 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: VIVITROL, VRAYLAR, Auvelity, ARISTADA, Zubsolv, CAPLYTA, SUBLOCADE, REXULTI.
Industry payments across MD — which companies pay providers there.
